reason report
sale growth momentum pois continu new product
bottom line share trade lower today compani
deliv basic in-lin quarter -- organ top-lin growth
lack guidanc rais limit oper leverag
look see number potenti driver
above-market growth outlook includ ramp adopt
freestyl libr roll-out libr eu anticip
launch upon fda approv instal base exit
base im script clearli track ahead
compani initi expect reach instal base
 intern end
inclin think adopt trend sustain
continu turnaround nutrit sale growth
solidli mid-single-digit rang consecut quarter
suggest busi could sustain healthi low-
mid-single-digit growth go forward like acceler
mitraclip sale -- alreadi grower -- follow strong
coapt data function mr mitral regurgit assum
volum pull-through ahead fda/reimburs approv
growth slow area includ too-slow sale
forc build neuromodul replac headwind
tough compar cardiac rhythm manag us
much execut stori compani complet
integr two recent major acquisit stj alr
drive new product cycl medic devic busi
steadi turnaround nutrit busi
quarter perform seem posit datapoint support
view success execut valuat
rel still-high expect keep us sidelin
acknowledg fundament seem improv
reiter mp pt believ build sustain growth
momentum acceler growth trajectori compel
view believ share near full valuat
deliv estim upsid even better execut behind recent
upcom new product launch believ share could
appreci price target appli multipl
ep estim basic line group multipl
sale estim move reflect fx impact ep
unchang sale estim move lower
organ report mainli reflect
neg guid fx impact littl
estim basic unchang vs
expect growth momentum sustain
compani inform leerink partner llc research
revenu mm ep includ stock compens expens exclud amort
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
ep estim
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rx trend deriv im health
rate share market perform price target abbott
like path top-lin growth acceler compani like reinvest
busi absorb acquisit includ alr stj deal
potenti bolster compani sale ep growth outlook becom
formid player med-tech diagnost even broader offer
near term uncertainti around integr stj alr like continu
reflect market sentiment beyond believ margin expans continu
remain key piec abbott long-term invest thesi abbott also attract investor
look safer defens stock healthi dividend yield current
increasingli volatil market help sustain current multipl abbott
succeed drive meaning margin expans nutrit busi margin
mid-teen level post-split still go increas cost effici
suppli chain manufactur abbott pipelin also number smaller
increment new product launch expect next year beyond
pend acquisit xienc stori larg play estim basic
stabl drug elut stent market share next year view abbott like
less acquisit immedi term two larg acquisit underway alreadi
estim reflect uncertainti around integr larg acquisit stj
expect share trade assum multipl
ep estim basic line large-cap med-tech group
clearli pois sale growth acceler next year believ current
valuat alreadi reflect potenti execut risk around new product launch --
heavili depend notabl freestyl libr mri-saf high power devic --
see opportun potenti downsid vs meaning clear-cut upsid
risk includ potenti slow end-market growth and/or increas competit
major product includ abbott xienc de total current abbott sale product
recal manufactur warn letter could push oper cost higher hinder sale
growth success pipelin execut key abbott growth stori product
approv time approv becom increasingli uncertain today challeng
regulatori environ success execut margin expans opportun
environ increas price pressur potenti acquisit could dilut
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report leerink partner estim factset visibl alpha
cardiovascular neuromodul
cardiovascular neuromodul
total cardiovascular neuromodul
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
cardiovascular neuromodul domest
cardiovascular neuromodul intern
total cardiovascular neuromodul
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report leerink partner estim factset visibl alpha
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report leerink partner estim
sg sale
 sale
diagnost contribut
neg fx impact littl
use sale baselin
organ growth rapid diagnost
contribut littl slightli
neg fx impact full year
adjust
littl less
adjust ep
diagnost contribut
neg fx impact
around
sale
use sale baselin
organ growth rapid diagnost
contribut littl posit fx
impact full year
somewhat
adjust
gain exchang
net interest expens
adjust ep
y/i mid-point
diagnost contribut posit
organ sale growth
fx impact
around
somewhat
sale
use sale baselin
organ growth rapid diagnost
contribut posit fx impact littl
somewhat
adjust
organ sale growth
baselin rapid diagnost
contribut littl posit
somewhat
adjust
fx impact
use sale baselin
organ growth rapid diagnost
contribut posit fx impact littl
somewhat
adjust
gain exchang
net interest expens
adjust ep
y/i mid-point
gain exchang
net interest expens
adjust ep
y/i mid-point
mid high-single-digit ex fx
low- mid-singl
mid high-single-
mid high-single-
improv sale
growth around
mid high-singl
growth diabet
sever
double-digit growth
mid- high singl
failur
singl digit declin
rhythm manag
mid-singl digit ex fx
mid-singl digit ex fx
mid-singl digit
mid-singl digit ex
approxim subject random investig site
approxim subject target receiv studi devic
assess mitraclip
percutan therapi heart
purpos coapt trial confirm safeti effect
mitraclip system treatment moderate-to-sever sever function mitral
regurgit fmr symptomat heart failur subject treat per
standard care determin site local heart team
appropri mitral valv surgeri random control trial provid
opportun strengthen add label claim regard safeti clinic
benefit mitraclip system symptomat heart failur patient
moderate-to-sever sever function mitral regurgit
fda approv
septemb present coapt data transcathet cardiovascular
therapeut tct annual meet landmark coapt studi met primari
safeti efficaci endpoint secondari endpoint show treatment
mitraclip plu medic therapi superior medic therapi alon reduc rate
heart failur hospit improv surviv two year therapeut mitral
valv intervent first demonstr posit outcom clinic trial
ail heart failur patient clinic signific secondari mitral regurgit
object studi evalu safeti effect
lva demonstr non-inferior hmii lva hmii use
treatment advanc refractori left ventricular heart failur
lva intend provid hemodynam support patient
advanc refractori left ventricular heart failur either short term support
bridg cardiac transplant btt myocardi recoveri long term
support destin therapi dt intend use insid
outsid hospit
y/i
ww growth rate report
point
point
point
point
point
point
cardiovascular neuromodul
cardiovascular neuromodul
cardiovascular neuromodul
cardiovascular neuromodul
cardiovascular neuromodul
cardiovascular neuromodul
rapid diagnost reflect sale aler inc acquir oct compar oper growth rate exclud result rapid diagnost
compar oper sale growth exclud impact exchang total abbott medic devic also includ prior year result stj exclud result amo
stj vascular closur busi compar oper sale growth also reflect reduct st jude medic histor sale
